Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia.

[1]  S. Pocock,et al.  Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome , 2018, Clinical Research in Cardiology.

[2]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  M. Vidovich,et al.  Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta‐analysis , 2018, American heart journal.

[4]  S. Pocock,et al.  Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. , 2017, International journal of cardiology.

[5]  S. Kiatchoosakun,et al.  Prognostic factors of in-hospital mortality in all comers with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention , 2016, Heart Asia.

[6]  B. Yan,et al.  Acute coronary syndrome in the Asia-Pacific region. , 2016, International journal of cardiology.

[7]  S. Pocock,et al.  Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long‐tErm follow‐uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia) , 2015, Clinical cardiology.

[8]  J. Ge,et al.  Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. , 2015, International journal of cardiology.

[9]  J. Mega,et al.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI , 2014, Nature Reviews Cardiology.

[10]  V. Fuster,et al.  Global Perspective on Acute Coronary Syndrome: A Burden on the Young and Poor , 2014, Circulation research.

[11]  Y. Jeong.  “East Asian Paradox”: Challenge for the Current Antiplatelet Strategy of “One-Guideline-Fits-All Races” in Acute Coronary Syndrome , 2014, Current Cardiology Reports.

[12]  Kelley Lee.  Health Policy in Asia and the Pacific: Navigating Local Needs and Global Challenges: Health Policy in Asia and the Pacific , 2014 .

[13]  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[14]  G. Lip,et al.  Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes , 2013, Thrombosis and Haemostasis.

[15]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[16]  F. Van de Werf,et al.  EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics. , 2013, American heart journal.

[17]  K. Okumura,et al.  Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version , 2010 .

[18]  T. Yamaguchi.  Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.